Table 2.

Participant Characteristics at Study Baseline

	Denosumab/Alendronate Sequence
	Denosumab Year 1 (N = 126)	Alendronate Year 2 (N = 115)
Race/ethnicity—white, n (%)	115 (91)	107 (93)
Age, mean (SD), years	65.1 (7.6)	65.1 (7.4)
Years since menopause, mean (SD)	18.2 (11.4)	17.9 (10.9)
BMD T-score at the start of each year, mean (SD)
Lumbar spine	–2.04 (1.16)	–1.61 (1.29)
Total hip	–1.60 (0.74)	–1.38 (0.74)
Femoral neck	–2.01 (0.55)	–1.84 (0.6)
Prior osteoporotic fracture, n (%)	47 (37.3)	41 (35.7)

N = number of participants randomized (year 1) or crossed over (year 2); n = number of participants with the characteristic of interest.

Abbreviations: BMD, bone mineral density SD, standard deviation.